Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METTL3 | Q86U44 | 1/20 | 0.60 |
| ▸ | CMA1 | P23946 | 7/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3626780 | 0.90 | METTL3 (0.51) | METTL3CMA1PLA2G4ALMNAHTR1D | |
| SCHEMBL3623776 | 0.89 | METTL3 (0.57) | METTL3CMA1PLA2G4ALMNAEGFR | |
| SCHEMBL3624158 | 0.84 | METTL3 (0.47) | METTL3CMA1NOTUM | |
| SCHEMBL3620362 | 0.81 | METTL3 (0.45) | METTL3CMA1PLA2G4ALMNAHTR1D | |
| SCHEMBL3626924 | 0.76 | CMA1 (0.42) | METTL3CMA1 | |
| SCHEMBL3627914 | 0.76 | METTL3 (0.46) | METTL3CMA1NOTUM | |
| SCHEMBL3623899 | 0.75 | METTL3 (0.49) | METTL3CMA1PLA2G4ALMNAEGFR | |
| SCHEMBL1044577 | 0.75 | METTL3 (0.86) | METTL3CMA1PLA2G4AEGFRLTB4R | |
| SCHEMBL1044579 | 0.75 | METTL3 (0.86) | METTL3CMA1PLA2G4AEGFRLTB4R | |
| Elvitegravir SCHEMBL726252 | 0.75 | METTL3 (1.00) | METTL3CMA1PLA2G4AEGFRLTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | claimed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | claimed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-7745459-B2 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | JAPAN TOBACCO INC. (JP) | 2006-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084665-A1 | Quinolizinone compound and use thereof as HIV integrase inhibitor | NQO2, ACE, CDK20 | METTL3 3971/4885CMA1 738/4885PLA2G4A 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.